Avalyn Pharma Inc. (AVLN) shareholders
Close on Nov 17, 2026Market cap $1.24BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (13.20%) | 5,835,259 | 13.20% | 13G (passive) amendment | Jun 30, 2026 |
| Novo Holdings A/S | 3,883,289 | 8.80% | 13G (passive) | Jun 30, 2026 |
| Simeon George Joint filing with SR One Capital Management, LLC (7.50%) | 3,308,649 | 7.50% | 13D (active) | May 1, 2026 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (6.00%), Perceptive Xontogeny Venture Fund II, L.P (5.10%) | 2,675,296 | 6.00% | 13G (passive) | Apr 30, 2026 |
| Aaron Cowen Joint filing with Suvretta Capital Management, LLC (5.60%) | 2,503,109 | 5.60% | 13D (active) | May 1, 2026 |
| Genesis VC Partners XV, LLC Joint filing with Norwest Venture Partners XV, LP (5.10%), NVP Associates, LLC (5.10%) and 2 more | 2,268,404 | 5.10% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AVLN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 5,835,259 | 13.16% | $192.10M | New | 0.01% |
| Novo Holdings A/S | 3,883,289 | 8.76% | $127.84M | New | 7.42% |
| Sr One Capital Management, LP | 3,308,649 | 7.46% | $108.92M | New | 10.48% |
| Perceptive Advisors LLC | 2,675,296 | 6.03% | $88.07M | New | 1.32% |
| Suvretta Capital Management, LLC | 2,503,109 | 5.65% | $82.40M | New | 1.51% |
| NVP Associates, LLC | 2,268,404 | 5.12% | $74.68M | New | 22.75% |
| Wellington Management Group Llp | 2,201,986 | 4.97% | $72.49M | New | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,735,231 | 3.91% | $57.12M | New | 0.01% |
| Catalio Capital Management, LP | 1,675,830 | 3.78% | $55.17M | New | 10.37% |
| T. Rowe Price Investment Management, Inc. | 1,602,745 | 3.62% | $52.76M | New | 0.03% |
| Eventide Asset Management, LLC | 1,375,486 | 3.10% | $45.28M | New | 0.61% |
| Bellevue Group AG | 1,350,000 | 3.05% | $44.44M | New | 0.94% |
| BlackRock, Inc. | 977,264 | 2.20% | $32.17M | New | 0.00% |
| Pivotal bioVenture Partners Investment Advisor LLC | 966,792 | 2.18% | $31.83M | New | 10.34% |
| Citadel Advisors LLC | 959,098 | 2.16% | $31.57M | New | 0.00% |
| Andera Partners | 929,824 | 2.10% | $30.61M | New | 14.82% |
| Jennison Associates LLC | 812,749 | 1.83% | $26.76M | New | 0.02% |
| Braidwell LP | 801,395 | 1.81% | $26.38M | New | 0.98% |
| Tpg Gp A, LLC | 773,069 | 1.74% | $25.45M | New | 0.51% |
| Vanguard Capital Management LLC | 739,770 | 1.67% | $24.35M | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 92 | 44M | 99.3% | 92 / 0 | 0 / 0 | 44M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AVLN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Small Cap Growth Fund | 1,231,620 | 2.78% | $35.46M | 0.40% | Jul 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 627,190 | 1.41% | $18.06M | 0.39% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 534,440 | 1.21% | $17.59M | 0.00% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 415,610 | 0.94% | $13.68M | 0.15% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 396,069 | 0.89% | $13.04M | 0.11% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 385,805 | 0.87% | $12.70M | 0.13% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 342,106 | 0.77% | $11.26M | 0.11% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 333,852 | 0.75% | $10.99M | 0.01% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 332,412 | 0.75% | $10.94M | 0.07% | Jun 30, 2026 |
| PGIM Jennison Health Sciences Fund | 318,463 | 0.72% | $9.17M | 0.66% | May 29, 2026 |
| Fidelity Blue Chip Growth Fund | 281,300 | 0.63% | $8.10M | 0.01% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 267,600 | 0.60% | $7.70M | 0.01% | May 31, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 217,777 | 0.49% | $7.17M | 0.14% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 192,656 | 0.43% | $6.34M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 186,980 | 0.42% | $5.38M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lyn Baranowski | Chief Executive Officer, Director | – | – | May 1, 2026 |
| Adam H. Golden | General Counsel | – | – | May 4, 2026 |
| Melissa Rhodes | Chief Operating Officer | – | – | May 1, 2026 |
| Douglas R. Carlson | Chief Financial Officer | – | – | May 1, 2026 |
| Howard Lazarus | Chief Medical Officer | – | – | May 1, 2026 |
| Robert J. Meyer | Director | – | – | Sep 17, 2026 |
| Heather D. Turner | Director | – | – | May 1, 2026 |
| Jon Congleton | Director | – | – | May 1, 2026 |
| Kate Haviland | Director | – | – | May 1, 2026 |
| Erin Lavelle | Director | – | – | May 1, 2026 |
| Jill Carroll | Director | 1,419,298 | 3.20% | May 1, 2026 |
| David Matthew Friedman | Director | – | – | Apr 29, 2026 |
| Llc Fmr | 10% owner | 2,056,081 | 4.64% | Nov 12, 2026 |
| Holdings A/S Novo | 10% owner | 3,883,289 | 8.76% | May 5, 2026 |
| Biomedical Innovation Master Investors (Cayman) II L.P. Wellington | 10% owner | 1,275,486 | 2.88% | May 1, 2026 |
| Sr One Capital Management, Llc | 10% owner | – | – | May 1, 2026 |
| Simeon George | 10% owner | 2,263,608 | 5.11% | May 1, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Llc Fmr 10% owner | Nov 10, 2026 | Sale | −47,889 | $30.28 | $1.45M | 2,056,081 |
| Llc Fmr 10% owner | Nov 10, 2026 | Sale | −5,565 | $29.56 | $164.50K | 2,103,970 |
| Llc Fmr 10% owner | Nov 9, 2026 | Sale | −1,339 | $29.75 | $39.84K | 2,109,535 |
| Llc Fmr 10% owner | Nov 9, 2026 | Sale | −173,661 | $29.06 | $5.05M | 2,110,874 |
| Holdings A/S Novo 10% owner | May 1, 2026 | Buy | +555,555 | $18.00 | $10.00M | 3,883,289 |
| Holdings A/S Novo 10% owner | May 1, 2026 | Conversion | +3,327,734 | – | – | 3,327,734 |
| Llc Fmr 10% owner | May 1, 2026 | Conversion | +727,585 | – | – | 727,585 |
| Llc Fmr 10% owner | May 1, 2026 | Conversion | +80,291 | – | – | 807,876 |
| Llc Fmr 10% owner | May 1, 2026 | Conversion | +872,868 | – | – | 1,680,744 |
| Llc Fmr 10% owner | May 1, 2026 | Conversion | +225,843 | – | – | 1,906,587 |
| Llc Fmr 10% owner | May 1, 2026 | Conversion | +377,948 | – | – | 2,284,535 |
| Simeon George 10% owner | May 1, 2026 | Conversion | +489,486 | – | – | 844,310 |
| Simeon George 10% owner | May 1, 2026 | Conversion | +1,419,298 | – | – | 1,419,298 |
| Simeon George 10% owner | May 1, 2026 | Conversion | +489,486 | – | – | 1,908,784 |
| Simeon George 10% owner | May 1, 2026 | Buy | +277,778 | $18.00 | $5.00M | 2,186,562 |
| Simeon George 10% owner | May 1, 2026 | Conversion | +354,824 | – | – | 354,824 |
| Simeon George 10% owner | May 1, 2026 | Buy | +277,777 | $18.00 | $5.00M | 1,122,087 |
| Jill Carroll Director | May 1, 2026 | Conversion | +1,419,298 | – | – | 1,419,298 |
| Jill Carroll Director | May 1, 2026 | Conversion | +489,486 | – | – | 1,908,784 |
| Jill Carroll Director | May 1, 2026 | Buy | +277,778 | $18.00 | $5.00M | 2,186,562 |
| Biomedical Innovation Master Investors (Cayman) II L.P. Wellington 10% owner | May 1, 2026 | Conversion | +1,275,486 | – | – | 1,275,486 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 6 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Avalyn Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 15,482 shares on Sep 3, 2026 over the last 90 days.
See a number that looks wrong?